Perioperative platelet transfusion: recommendations of the Agence française de sécurité sanitaire des produits de santé (AFSSaPS) 2003

PurposeTo present the recommendations of the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSaPS; French Safety Agency for Health Products).MethodsA panel of experts reviewed and graded the literature on platelet transfusions; recommendations were formulated.Main findingsThreshold platelet counts (PC) for transfusions in the perioperative context have not been clearly defined and should be determined by the existence of hemorrhagic risk factors. In the case of commonly practiced invasive procedures, the recommendation is to transfuse in orderto achieve PC > 50,000 · μL−1. In the absence of platelet dysfunction, regardless of the type of surgery, the standard hemorrhagic riskthreshold for surgery is 50,000 · μL−1. It has not been proven that the risk threshold is different according to the type of surgery. For neurosurgery and ophthalmologic surgery involving the posterior segment of the eye, a PC of 100,000 · μL−1 is required. For axial regional anesthesia, a PC of 50,000 · μL−1 is sufficient for spinal anesthesia; a PC of 80,000 · μL−1 has been proposed for epidurals. During massive transfusion, prophylactic platelet infusion cannot be recommended beyond a loss of two blood volumes in less than 24 hr (Professional Consensus). As for the therapeutic transfusion of plasma and/or platelets, as much as possible, platelet deficit should be documented with test results (PC and fibrinogen) before transfusing. In the event of bleeding, platelet transfusion may precede plasma infusion. However, although this recommendation has been the subject of several professional consensus agreements, it is not based on any randomized studies.ConclusionThreshold PC for perioperative transfusions have not been clearly defined and most recommendations are the result of a professional consensus.RésuméObjectifPrésenter les recommandations de l’Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSaPS).MéthodeUn panel d’experts a revu et évalué la documentation sur les transfusions de plaquettes; des recommandations ont été formulées.Constatations principalesLe décompte plaquettaire seuil (DP) pour les transfusions périopératoires n’est pas clairement défini et doit être déterminé par l’existence de facteurs de risque hémorragique. Dans le cas de gestes invasifs pratiqués fréquemment, on recommande de transfuser pour atteindre un DP > 50 000 · μL−1. En l’absence de dysfonction plaquettaire, peu importe le type de chirurgie, le seuil du risque hémorragique normal de la chirurgie est de 50 000 · μL−1. On n’a pas prouvé que le seuil de risque dépend du type de chirurgie. En neurochirurgie, et ophtalmologique touchant le segment postérieur de l’œil, il faut un DP de 100 000 · μ−1. En anesthésie régionale axiale, un DP de 50 000 · μL−1 est suffisant pour la rachianesthésie; un DP de 80 000 · μL−1 a été proposé pour les péridurales. Pendant la transfusion massive, la perfusion prophylactique de plaquettes ne peut être recommandée au delà d’une perte de deux masses sanguines en moins de 24 h (Consensus professionnel). Comme pour la transfusion thérapeutique de plasma et/ou de plaquettes, autant que possible, le déficit de plaquettes doit être documenté avec les résultats de tests (DP et fibrinogène) avant de transfuser. En cas d’hémorragie, la transfusion de plaquettes peut précéder la transfusion de plasma. Cependant, même si cette recommandation a fait l’objet de certains accords du consensus professionnel, il n’est fondé sur aucune étude randomisée.ConclusionLe DP seuil pour les transfusions périopératoires n’a pas été clairement défini et la plupart des recommandations sont le résultat d’un consensus professionnel.

[1]  S. O'kelly,et al.  Bleeding time: is it a useful clinical tool? , 1992, British journal of anaesthesia.

[2]  A. Marcus,et al.  Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. , 1991, The Journal of clinical investigation.

[3]  C. Patrono Antiplatelet strategies*1 , 2002 .

[4]  S. Crawford,et al.  Complications of Fiberoptic Bronchoscopy in Thrombocytopenic Patients , 1993, Chest.

[5]  E. Spitznagel,et al.  Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. , 1994, The Journal of thoracic and cardiovascular surgery.

[6]  Andy Hay,et al.  Bleeding complications in thrombocytopenic patients undergoing ophthalmic surgery. , 1990, American journal of ophthalmology.

[7]  M. Syrjälä,et al.  Massive blood transfusion exceeding 50 units of plasma poor red cells or whole blood: the survival rate and the occurrence of leukopenia and acidosis. , 1999, Injury.

[8]  P. Neame,et al.  Coagulopathy related to dilution and hypotension during massive transfusion , 1985, Critical care medicine.

[9]  M. J. Rohrer,et al.  Effect of hypothermia on the coagulation cascade , 1992, Critical care medicine.

[10]  J. Vermylen,et al.  Anticoagulants and Spinal‐Epidural Anesthesia , 1994, Anesthesia and analgesia.

[11]  Eric J Topol,et al.  Platelet GPIIb-IIIa blockers , 1999, The Lancet.

[12]  W. Ouwehand,et al.  Guidelines for platelet transfusions , 1992 .

[13]  P Coriat,et al.  Role of the hematocrit in a rabbit model of arterial thrombosis and bleeding. , 1999, Anesthesiology.

[14]  F. Degos,et al.  [Practices of transcutaneous liver biopsies in France. Results of a retrospective nationwide study]. , 2001, Gastroenterologie clinique et biologique.

[15]  J. Posner,et al.  Spinal Subdural Hematomas Complicating Lumbar Puncture: Occurrence in Thrombocytopenic Patients , 1974 .

[16]  S. Hiippala Replacement of Massive Blood Loss , 1998, Vox sanguinis.

[17]  C. Valeri,et al.  Reversible Inhibition of Human Platelet Activation by Hypothermia In Vivo and In Vitro , 1994, Thrombosis and Haemostasis.

[18]  G. FitzGerald,et al.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[19]  Scott W McCulloch Effect of hypothermia on the coagulation cascade: Rohrer MJ, Natale AM Crit Care Med 20:1402–1405 Oct 1992 , 1993 .

[20]  M. P. Harvey,et al.  Massive blood transfusion in a tertiary referral hospital , 1995, The Medical journal of Australia.

[21]  J. Levin,et al.  A Critical Reappraisal of the Bleeding Time* , 1990, Seminars in thrombosis and hemostasis.

[22]  B. Gertz,et al.  Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers , 2000, Journal of clinical pharmacology.

[23]  D Stainsby,et al.  Management of massive blood loss: a template guideline. , 2000, British journal of anaesthesia.

[24]  P. Rebulla,et al.  Trigger for platelet transfusion. , 2000, Vox sanguinis.

[25]  J. Kelton,et al.  Thrombocytopenia at delivery: A prospective survey of 6715 deliveries , 1990, American journal of obstetrics and gynecology.

[26]  D. Leys,et al.  Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001--summary statement. , 2002, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[27]  B. Griffith,et al.  Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. , 1998, The Annals of thoracic surgery.

[28]  B. Gutsche,et al.  Epidural Anesthesia in Pregnant Patients With Low Platelet Counts , 1988, Obstetrics and gynecology.

[29]  G. Escolar,et al.  Experimental basis for the use of red cell transfusion in the management of anemic‐thrombocytopenic patients , 1988, Transfusion.

[30]  A. Schafer,et al.  Effects of nonsteroidal anti-inflammatory therapy on platelets. , 1999, The American journal of medicine.

[31]  Y. Beilin,et al.  Safe Epidural Analgesia in Thirty Parturients with Platelet Counts Between 69,000 and 98,000 mm-3 , 1997, Anesthesia and analgesia.

[32]  A. E. Horvath,et al.  Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. , 1994, JAMA.

[33]  E. Vahtera,et al.  Hemostatic Factors and Replacement of Major Blood Loss with Plasma-Poor Red Cell Concentrates , 1995, Anesthesia and analgesia.

[34]  D. Heimbach,et al.  Prophylactic platelet administration during massive transfusion. A prospective, randomized, double-blind clinical study. , 1986, Annals of surgery.

[35]  S. Rolbin,et al.  Epidural anaesthesia and thrombocytopenia , 1989, Anaesthesia.

[36]  M. Contreras Final statement from the consensus conference on platelet transfusion , 1998, Transfusion.